ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO849

The 10-Year Effects of Lifestyle Modifications on Kidney Outcomes

Session Information

Category: Health Maintenance‚ Nutrition‚ and Metabolism

  • 1400 Health Maintenance‚ Nutrition‚ and Metabolism


  • Lavenburg, Linda-Marie Ustaris, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Cohen, Jordana B., University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Schaubel, Douglas Earl, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Reese, Peter P., University of Pennsylvania, Philadelphia, Pennsylvania, United States

Group or Team Name

  • Renal-Electrolyte and Hypertension, University of Pennsylvania

Obesity is a global epidemic associated with risk factors for chronic kidney disease (CKD). The Action for Health in Diabetes (Look AHEAD) trial showed greater weight loss after exposure to intensive lifestyle intervention compared to diabetes support and education (i.e., usual care). Weight loss interventions can improve short-term kidney outcomes, but larger longitudinal studies on non-surgical obesity treatments are needed. We investigated the effects of weight loss from lifestyle modifications on kidney function over ten years.


We performed a retrospective cohort study of 4,901 individuals with type 2 diabetes and BMI ≥25kg/m2 using the Look AHEAD dataset which was collected between 2001-2015. We used linear mixed effect models to evaluate for within-individual changes of mean values and slope of estimated glomerular filtration rate (eGFR) (primary outcome) and urine albumin to creatinine ratio (UACR) (secondary outcome) between randomization arms. We evaluated for effect modification by baseline kidney function and visit year using the Wald test and a two-sided significance level of 0.05.


At baseline, mean eGFR in both randomization arms was 89ml/min/1.73m2 and 83% of participants had normal albuminuria. Over 10 years, the intervention arm had a slightly higher mean eGFR compared to the usual care arm (beta-coefficient (B): 0.5, p=0.04). The intervention improved loss of eGFR after year two (B: 0.78, pinteraction=0.001). The magnitude of the intervention's effect differed by year with the slowest decline in eGFR by 1.20ml/min/1.73m2 (p=0.002) at year 3. Among individuals with a baseline eGFR <80ml/min/1.73m2, the mean eGFR in the intervention arm was 1.25ml/min/1.73m2 (p=0.02) higher than the usual care arm. However, there was no difference in mean UACR (B: -0.001, p=0.94) or slope of UACR (B: 0.0002, p=0.80) between arms.


Among individuals at high risk for CKD, exposure to intensive lifestyle intervention resulted in slower eGFR loss by year 2 and slightly higher kidney function over 10 years compared to usual care. Individuals with lower kidney function had greater benefit from the intervention than those with higher kidney function. Participation in a lifestyle modification program is recommended for individuals with excess body weight and can slow progression to CKD in at risk populations.


  • Other NIH Support